Therapeutic Action
Opioid analgesic
PDF page 99
Loading InternPractice…
Drug reference
Opioid analgesic
PDF page 99
Moderate pain, alone or in combination with a non-opioid analgesic
PDF page 99
Do not administer to patients with acute respiratory depression or asthma attack. May cause: constipation, nausea, vomiting, drowsiness, dizziness; rarely: respiratory depression, allergic reactions, dependence, withdrawal syndrome. Do not combine with: other agonist opioids such as morphine (increased risk of respiratory depression); agonist-antagonist opioids such as buprenorphine, nalbuphine, pentazocine (competitive action). Management of respiratory depression includes assisted ventilation and/or administration of naloxone. Pregnancy: no contra-indication. The newborn infant may develop withdrawal symptoms, respiratory depression and drowsiness in the event of prolonged administration of large doses at rd the end of the 3 trimester. In this event, closely monitor the newborn infant. Breast-feeding: use with caution, for a short period (2-3 days), at the lowest effective dose. Monitor the mother and the infant: in the event of excessive drowsiness, stop treatment.
PDF pages 99, 100
30 mg codeine phosphate tablet
PDF page 99
Child over 12 years and adult: 30 to 60 mg every 4 to 6 hours; maximum 240 mg daily
PDF page 99
According to clinical evolution; as short as possible.
PDF page 99
Administer an appropriate laxative (e.g. lactulose) if analgesic treatment continues more than 48 hours. In some countries, codeine is on the list of narcotics: follow national regulations.
PDF page 100
- Below 25 °C
PDF page 100
30 to 60 mg every 4 to 6 hours; maximum 240 mg daily
PDF page 99